Uses of Etivas 20

Etivas 20 is mainly used in the support and treatment of primary hypercholesterolemia with the main ingredients being Simvastatin and Ezetimibe. Let's find out more details about the use and use of Etivas 20 drug through the following article.

Etivas 20 belongs to the group of cardiovascular drugs with the active ingredient Simvastatin 20mg and Ezetimibe 10mg. Used in support to help lower bad cholesterol and fat. Etivas 20 is prepared in the form of tablets packed in boxes of 3 blisters x 10 tablets, boxes of 10 blisters x 10 tablets.

Etivas 20 is used in the following cases:
Primary hypercholesterolemia, adjunctive treatment with diet to reduce elevation of total cholesterol (C-total), apolipoprotein B (Apob), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and non-high-density lipoprotein cholesterol and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary or mixed hyperlipidemia . Homozygous Familial Hypercholesterolemia (HoFH) Vytorin is indicated for the reduction of elevated total cholesterol and LDL-C in elderly patients with HoFH. Vytorin should be used as an adjunct to other lipid-lowering treatments in these patients or if these are not available. In addition to an appropriate diet, scientific lifestyle changes (exercise, weight loss if overweight and stopping smoking) can also help promote the effects of Etivas 20 better. Please consult qualified medical professionals for more details.

Usage:
Etivas 20 should only be used by adults, not recommended for children. Patients should be on a cholesterol-lowering diet before initiating and during treatment. Patient-specific dosing is based on baseline LDL-C levels, patient response, and treatment goals. The drug should be taken once a day in the evening, with or without food. It is recommended to use a low starting dose at which the drug is effective. Dosage:
Extended dose from 1 tablet (10/10 mg)/day to 10/80 mg/day, taken once in the evening. When dosage adjustment is required, it is necessary to follow the interval of at least 4 weeks, increase to a maximum of 10/80 mg/day and take it once in the evening. The 10/80 mg dose is only recommended for use in patients at high risk for cardiovascular complications or who have not achieved treatment goals at lower doses. The recommended dose for patients with homozygous familial hypercholesterolemia is about 10/40 mg/day or 10/80 mg/day in the evening. The 10/80 mg dose should only be used when the benefits outweigh the risks. Etivas 20 should be used as an adjunct to other lipid-lowering treatments (such as LDL apheresis) in these patients or if these are not available. No dose adjustment of Etivas 20 is required in patients with moderate renal impairment. In case of severe renal impairment (creatinine clearance ≤ 30 mL/min), a dose of 10/10 mg/day should be used and close monitoring is required. Elderly: No dose adjustment of Etivas is necessary. Hepatic impairment: No dose adjustment is required in patients with mild hepatic impairment. The drug should not be used in patients with moderate or severe hepatic impairment. If combined with other drugs, the drug should be taken 2 hours before or 4 hours after taking the bile acid absorber. In combination with Etivas 20 in patients receiving Cyclosporin or Danazol, the dose should not exceed 10/10 mg/day. Do not exceed 10/20 mg/day when used in combination with patients taking Amiodarone, Verapamil or Diltiazem, the dose should not exceed 10/40 mg/day while on Amlodipine.

Etivas 20 should not be used in the following cases:
Patients with hypersensitivity to active ingredients Simvastatin and Ezetimibe Or any of the excipients of the drug. Active liver disease Persistent elevation of plasma transaminases of unknown cause. Pregnant and breastfeeding. Co-administration with strong inhibitors of CYP3A4 (such as Posaconazole, Itraconazole, Ketoconazole, HIV Protease inhibitors, Drythromycin, Doceprevir, Telaprevir, Clarithromycin, Telithromycin and Nefazodone). Used in combination with Danazol, Gemfibrozil, Cyclosporin. Secondary myopathy

During the use of Etivas 20, patients may experience some unwanted side effects such as:
Pain or muscle weakness with no known cause. Fever, fatigue Dark urine, little or no urination, burning pain when urinating, dark urine. Swelling, itching, weight gain or loss Thirst, dry mouth, fruity breath, drowsiness, dry skin, blurred vision. Nausea, loss of appetite with upper abdominal pain. Clay-colored stools Jaundice of the skin and eyes. Headache Joint pain Constipation, abdominal pain, irritability, indigestion Mild skin rash. Insomnia Stuffy nose, sore throat, sneezing Tell your doctor, pharmacist to treat all side effects that patients experience while taking Etivas 20.

Strong inhibitors of CYP3A4 (eg Itraconazole, Nefazodone, Ketoconazole, Posaconazole, Erythromycin, Boceprevir Clarithromycin, Telithromycin, HIV Protease Inhibitors, Telaprevir). Gemfibrozil, Danazol, Cyclosporine. It has been reported that the combined use of Gemfibrozil with Etivas 20 resulted in an approximately 1.7-fold increase in total Ezetimibe exposure, which was not clinically relevant.

Consideration should be given to the use of statin drugs in patients with risk factors for muscle damage. Drugs belonging to the statin group can cause adverse reactions to the muscular system such as myositis, muscle atrophy, especially in patients with risk factors (elderly over 65 years old, with hypothyroidism). uncontrolled, kidney disease).
Consult a doctor before using Etivas 20 to drive or operate machinery.
Pregnant and lactating women should consider and consult their doctor or pharmacist before taking Etivas. Drugs that have been clinically tested still have risks when used.